ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2009
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 91 citations in OpenAlex.
- PET Imaging Radiotracers of Chemokine Receptors.Molecules (Basel, Switzerland) · 2021Review
- PET Radiotracers for CNS-Adrenergic Receptors: Developments and Perspectives.Molecules (Basel, Switzerland) · 2020Review
- pH-Responsive Polymers for Improving the Signal-to-Noise Ratio of Hypoxia PET Imaging with [Macromolecular rapid communications · 2020Article
- Approaches to PET Imaging of Glioblastoma.Molecules (Basel, Switzerland) · 2020Review
- Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer.Neoplasia (New York, N.Y.) · 2019Article
- Performing multi-step chemical reactions in microliter-sized droplets by leveraging a simple passive transport mechanism.Lab on a chip · 2017Article
- A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines.Journal of visualized experiments : JoVE · 2017Article
- Clinical PET-MR Imaging in Breast Cancer and Lung Cancer.PET clinics · 2016Review
- Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.Molecular imaging and biology · 2015Article
- Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy.EJNMMI research · 2014Article
- PET tracers for serotonin receptors and their applications.Central nervous system agents in medicinal chemistry · 2014Review
- Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.Molecular imaging and biology · 2013Article
- The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors.Current pharmaceutical biotechnology · 2013Review
- Imaging in oncology--over a century of advances.Nature reviews. Clinical oncology · 2012Review
- Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL.Molecular imaging and biology · 2012Article
- Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer.Frontiers in oncology · 2012Article
- Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation.Pharmaceutics · 2012Article
- PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel 18F-labeled biotin derivative.Molecular imaging and biology · 2011Article
- The next generation of positron emission tomography radiopharmaceuticals in oncology.Seminars in nuclear medicine · 2011Review
- A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.Dalton transactions (Cambridge, England : 2003) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
This review article discusses PET agents, other than (18)F-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non-(18)F-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the therapeutic response. Four sections related to the nature of the tracers are included: radiotracers of DNA synthesis, such as the 2 most promising agents, the thymidine analogs 3'-(18)F-fluoro-3'-deoxythymidine and (18)F-1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)thymine; agents for PET imaging of hypoxia within tumors, such as (60/62/64)Cu-labeled diacetyl-bis(N(4)-methylthiosemicarbazone) and (18)F-fluoromisonidazole; amino acids for PET imaging, including the most popular such agent, l-[methyl-(11)C]methionine; and agents for the imaging of tumor expression of androgen and estrogen receptors, such as 16beta-(18)F-fluoro-5alpha-dihydrotestosterone and 16alpha-(18)F-fluoro-17beta-estradiol, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.